Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience

<b>Background:</b> Our aim was to describe the clinical outcome and safety of the sequential treatment with off-label dalbavancin in patients with spondylodiscitis that is caused by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <b>Methods</b>: We retr...

Full description

Bibliographic Details
Main Authors: Maria Mazzitelli, Milo Gatti, Vincenzo Scaglione, Daniele Mengato, Marco Trevenzoli, Andrea Sattin, Federico Pea, Anna Maria Cattelan
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Antibiotics
Subjects:
dalbavancin
MRSA
spondylodiscitis
off-label
vertebral infections
TDM
Online Access:https://www.mdpi.com/2079-6382/11/10/1377

Internet

https://www.mdpi.com/2079-6382/11/10/1377

Similar Items